loading
前日終値:
$162.22
開ける:
$163.44
24時間の取引高:
460.86K
Relative Volume:
0.48
時価総額:
$8.60B
収益:
$708.24M
当期純損益:
$-188.30M
株価収益率:
-43.89
EPS:
-3.7392
ネットキャッシュフロー:
$-70.99M
1週間 パフォーマンス:
-3.51%
1か月 パフォーマンス:
-19.58%
6か月 パフォーマンス:
-10.90%
1年 パフォーマンス:
+26.65%
1日の値動き範囲:
Value
$163.44
$169.96
1週間の範囲:
Value
$155.18
$170.80
52週間の値動き範囲:
Value
$120.12
$260.19

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
名前
Axsome Therapeutics Inc
Name
セクター
Healthcare (1051)
Name
電話
(212) 332-3241
Name
住所
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
職員
925
Name
Twitter
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
AXSM's Discussions on Twitter

Compare AXSM vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AXSM icon
AXSM
Axsome Therapeutics Inc
164.11 8.60B 708.24M -188.30M -70.99M -3.7392
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
510.27 129.33B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
237.88 94.97B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
801.50 82.52B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
849.70 53.43B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
372.00 42.08B 5.76B 514.49M 1.10B 4.4813

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-23 再開されました Truist Buy
2026-07-21 開始されました BMO Capital Markets Outperform
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-01 開始されました B. Riley Securities Buy
2025-09-03 再開されました Wells Fargo Overweight
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 開始されました Oppenheimer Outperform
2025-04-07 開始されました Jefferies Buy
2025-02-11 開始されました Deutsche Bank Buy
2024-12-31 繰り返されました Mizuho Outperform
2024-09-03 開始されました Wells Fargo Overweight
2024-08-06 アップグレード BofA Securities Neutral → Buy
2024-07-22 開始されました Needham Buy
2024-04-29 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-03-19 開始されました Robert W. Baird Outperform
2024-02-06 開始されました UBS Buy
2024-01-25 開始されました RBC Capital Mkts Outperform
2023-12-13 開始されました Citigroup Buy
2023-08-08 アップグレード BofA Securities Underperform → Neutral
2023-01-05 開始されました Piper Sandler Neutral
2022-11-01 開始されました Loop Capital Buy
2022-09-07 再開されました Mizuho Buy
2021-08-10 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-06-10 開始されました Berenberg Buy
2021-01-08 開始されました Jefferies Buy
2020-12-16 開始されました Mizuho Buy
2020-09-29 開始されました BofA Securities Underperform
2020-09-10 開始されました Morgan Stanley Overweight
2020-04-28 繰り返されました H.C. Wainwright Buy
2020-04-14 開始されました Cowen Outperform
2019-12-30 繰り返されました H.C. Wainwright Buy
2019-12-17 繰り返されました H.C. Wainwright Buy
2019-12-16 繰り返されました Guggenheim Buy
2019-10-16 開始されました Guggenheim Buy
2019-09-18 開始されました William Blair Outperform
2019-05-28 開始されました SunTrust Buy
2019-05-23 繰り返されました H.C. Wainwright Buy
2019-04-08 開始されました SVB Leerink Outperform
2019-03-15 繰り返されました H.C. Wainwright Buy
2016-10-03 再開されました Brean Capital Buy
2015-12-15 開始されました Cantor Fitzgerald Buy
2015-12-14 開始されました Ladenburg Thalmann Buy
すべてを表示

Axsome Therapeutics Inc (AXSM) 最新ニュース

pulisher
Oct 14, 2026

RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada

Oct 14, 2026
pulisher
Oct 13, 2026

Why Axsome Therapeutics shares are falling today - Quiver Quantitative

Oct 13, 2026
pulisher
Oct 13, 2026

Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Axsome Therapeutics, Inc. (19X.F) Stock Price, News, Quote & History - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – DUS:19X - TradingView

Oct 13, 2026
pulisher
Oct 13, 2026

Axsome Therapeutics Stock: 12 Straight Red Days, Down 15% - Trefis

Oct 13, 2026
pulisher
Oct 12, 2026

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail

Oct 12, 2026
pulisher
Oct 12, 2026

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail

Oct 12, 2026
pulisher
Oct 12, 2026

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Motley Fool

Oct 12, 2026
pulisher
Oct 10, 2026

Tangible book value per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView

Oct 10, 2026
pulisher
Oct 10, 2026

Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities - The Globe and Mail

Oct 10, 2026
pulisher
Oct 10, 2026

Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss - Trefis

Oct 10, 2026
pulisher
Oct 09, 2026

H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo

Oct 09, 2026
pulisher
Oct 09, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% - Trefis

Oct 09, 2026
pulisher
Oct 08, 2026

Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018 -- Data Talk - Moomoo

Oct 08, 2026
pulisher
Oct 08, 2026

Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $295.00 by Analysts at Royal Bank Of Canada - MarketBeat

Oct 08, 2026
pulisher
Oct 08, 2026

Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo

Oct 08, 2026
pulisher
Oct 08, 2026

Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days - Trefis

Oct 08, 2026
pulisher
Oct 07, 2026

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool

Oct 07, 2026
pulisher
Oct 07, 2026

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance

Oct 07, 2026
pulisher
Oct 07, 2026

Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. - Stock Titan

Oct 07, 2026
pulisher
Oct 07, 2026

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 - GlobeNewswire

Oct 07, 2026
pulisher
Oct 06, 2026

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting - Lelezard

Oct 06, 2026
pulisher
Oct 05, 2026

Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance

Oct 05, 2026
pulisher
Oct 02, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 02, 2026
pulisher
Oct 01, 2026

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 - webull.com

Oct 01, 2026
pulisher
Sep 29, 2026

EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - tradingview.com

Sep 29, 2026
pulisher
Sep 29, 2026

Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat

Sep 29, 2026
pulisher
Sep 29, 2026

Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative

Sep 29, 2026
pulisher
Sep 29, 2026

Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - tradingview.com

Sep 29, 2026
pulisher
Sep 29, 2026

Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat

Sep 29, 2026
pulisher
Sep 29, 2026

Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo

Sep 29, 2026
pulisher
Sep 29, 2026

Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com

Sep 29, 2026
pulisher
Sep 29, 2026

Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - Yahoo Finance

Sep 29, 2026
pulisher
Sep 28, 2026

Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 28, 2026
pulisher
Sep 26, 2026

Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo

Sep 26, 2026
pulisher
Sep 25, 2026

Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo

Sep 25, 2026
pulisher
Sep 25, 2026

AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com

Sep 25, 2026
pulisher
Sep 24, 2026

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga

Sep 24, 2026
pulisher
Sep 23, 2026

Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com

Sep 23, 2026
pulisher
Sep 23, 2026

Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - Yahoo Finance

Sep 23, 2026
pulisher
Sep 21, 2026

Axsome Therapeutics Announces Results of the Shared Goals - globenewswire.com

Sep 21, 2026
pulisher
Sep 19, 2026

Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance

Sep 19, 2026
pulisher
Sep 19, 2026

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - Yahoo Finance

Sep 19, 2026
pulisher
Sep 19, 2026

Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance

Sep 19, 2026

Axsome Therapeutics Inc (AXSM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Axsome Therapeutics Inc (AXSM) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Jacobson Mark L.
Chief Operating Officer
Sep 03 '26
Sale
208.65
10,000
2,086,500
0
Mark Jacobson
Officer
Sep 03 '26
Proposed Sale
208.35
10,000
2,083,500
0
Herriot Tabuteau
Officer
Aug 06 '26
Proposed Sale
210.13
4,660
979,206
0
TABUTEAU HERRIOT
Chief Executive Officer
Aug 06 '26
Sale
213.95
4,660
997,007
7,229
TABUTEAU HERRIOT
Chief Executive Officer
Aug 06 '26
Option Exercise
4.95
4,660
23,067
11,889
Herriot Tabuteau
Officer
Aug 05 '26
Proposed Sale
212.85
45,004
9,579,101
0
TABUTEAU HERRIOT
Chief Executive Officer
Aug 05 '26
Option Exercise
4.95
45,004
222,770
52,233
TABUTEAU HERRIOT
Chief Executive Officer
Aug 05 '26
Sale
212.01
45,004
9,541,298
7,229
TABUTEAU HERRIOT
Chief Executive Officer
Jul 01 '26
Sale
240.25
49,666
11,932,256
7,229
TABUTEAU HERRIOT
Chief Executive Officer
Jul 01 '26
Option Exercise
4.95
49,666
245,847
56,895
$56.25
price up icon 3.46%
CAI CAI
$31.29
price up icon 3.40%
$136.81
price up icon 0.39%
$107.30
price up icon 0.44%
$64.27
price up icon 1.32%
$57.57
price down icon 1.37%
大文字化:     |  ボリューム (24 時間):